We respond to the consultation by The Medicines and Healthcare Products Regulatory Agency (MHRA) on whether to reclassify Lovima, a progestogen-only contraceptive pill, as Pharmacy (P) medicine.
We respond to the consultation by The Medicines and Healthcare Products Regulatory Agency (MHRA) on whether to reclassify Hana, a progestogen-only contraceptive pill, as Pharmacy (P) medicine.
The Department of Health and Social Care is consulting on whether to continue to allow home use of mifepristone and misoprostol for early medical abortion (EMA) up to 10 weeks gestation after the pandemic. In our consultation response, we make the case for making this measure permanent in England.
The Welsh Government is consulting on whether to continue to allow home use of mifepristone and misoprostol for early medical abortion (EMA) up to 10 weeks gestation after the pandemic. In our consultation response, we make the case for making this measure permanent in Wales.
We make the case for long-term, sustainable investment in Public Health, Education and Training.
FSRH's response to NHS England / Improvement’s consultation on proposed legislative options to further develop Integrated Care Systems (ICS).
FSRH Submission to the NICE consultation on the Quality Standard for Heavy Menstrual Bleeding
FSRH and the Faculty of Public Health representation to the Treasury on the Comprehensive Spending Review 2020.
We respond to an inquiry on workforce burnout and resilience in the NHS and Social Care by the Health and Social Care Committee.
This survey by NHS England and NHS Improvement looks at new and innovative ways of working that have been developed across the NHS during the COVID-19 pandemic. In our response we outline changes to SRH care during the pandemic, including remote consultations, prescriptions and medical collection systems, postpartum contraception, and telemedicine for abortion care.
